BullFrog AI CEO Vin Singh will deliver a keynote at the AIDDD Summit discussing advances in AI-driven drug discovery, including faster timelines, cost reductions, and promising clinical trial results. He will address ongoing challenges in later-stage drug development and emphasize the role of AI in improving drug success rates and patient outcomes. Singh will also share insights from BullFrog AI’s nine years of experience, highlighting the importance of combining AI with scientific expertise for measurable results. This keynote underscores AI's growing impact on pharmaceutical R&D and future medicine development.
BullFrog AI CEO Vin Singh's keynote at the AIDDD Summit provides context for readers following AI and health innovation. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 27, 2026 17:43 WIB: Of 150 priced US health stocks, 69 rose and 68 fell today. Notable movers include INO (Inovio Pharmaceuticals Inc) at USD 0.90 with a 1-day change of +3.78% and Pluang order activity of 13% Sell / 87% Buy, BNGO (BioNano Genomics Inc) at USD 1.12 down 3.45% with 100% Sell orders, and CRON (Cronos Group Inc) at USD 3.41 up 3.02%. Typical hold times on Pluang range from 23 to 51 days.
CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...
eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...
Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...
